ST. PAUL, Minn. & ST. LOUIS--(BUSINESS WIRE)--Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, announced that David Stevens has joined the organization as global chief commercial officer (CCO). Stevens will spearhead the commercial, business development, and research and development activities for the business to ensure continued growth, expansion, and innovation.
“David brings a breadth of industry experience and a depth of commercial expertise that is essential for driving Kindeva’s enhanced scope and scale,” said Kindeva CEO Milton Boyer. “His role is vital to our continued success as a premier CDMO and, in turn, the success of our partners bringing a broad range of drug delivery solutions to market.”
Stevens has more than 20 years of international operations and commercial experience across both the CDMO and contract research organization (CRO) sectors. Prior to Kindeva, Stevens was CEO of advanced therapy CDMO Arranta Bio (acquired by Recipharm in 2022), where he successfully built out two advanced biologics development and GMP manufacturing facilities. He held multiple roles at AMRI prior — leading the company’s drug product business unit through significant growth and capacity expansion. Throughout his tenure, he also held positions at Aptuit, Inveresk, and Charles River Laboratories. Stevens has an MBA in strategy, finance, and marketing from the University of Edinburgh.
“The Kindeva organization has a strong history of achievement, expertise, and the infrastructure to handle an extensive range of critical complex drug delivery challenges,” Stevens said. “I am excited to work with the incredible experts bringing many life-changing therapies and the highest-quality products to patients, and I am looking forward to leveraging my commercial, operational, and strategic background to enable continued success for our partners worldwide.”
About Kindeva Drug Delivery
Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including autoinjectors, inhalers, transdermal patches, and microneedles. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing and drug-device product assembly. Kindeva serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.